Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
Tharimmune Presents Phase 1 Data On TH104 For Moderate-To-Severe Pruritus In Chronic Liver Disease At ACG 2024; No Opioid Withdrawal Effects Observed, Supporting Safety Profile With Phase 2 Results Expected In 2025
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.